Renal cell carcinoma management: A step to nano-chemoprevention

• Published in: Life sciences (1973) Vol. 308; p. 120922
• Main Authors: Siddiqi, Aisha, Rani, Madhu, Bansal, Preeti, Rizvi, M. Moshahid Alam
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2022
• Subjects: Chemoprevention; Nano-chemoprevention; Nanotechnology; Phytochemicals; Renal cell carcinoma; Targeted drug delivery; PCNA; Nano-chemoprevention; MRI; EPR; JNK; TFPI-2; RTK; INF-α; SLNPs; AQP1; DNMT; Targeted drug delivery; Renal cell carcinoma; NSLC; VHL; DPPC; HMC; PDT; TRAIL; SFCS; EGCG; VEGF; Chemoprevention; IL-2; GNPs; MAPK; EMT; bFGF; PAMAM; CT; STAT; PEG; PLGA; RCC; Phytochemicals; MMP-2; PEI; CFMs; TGF-β1; PLIN2; MMP-9; Nanotechnology
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2022.120922

Renal cell carcinoma (RCC) is one of the most common kidney cancers, responsible for nearly 90 % of all renal malignancies. Despite the availability of many treatment strategies, RCC still remains to be an incurable disease due to its resistivity towards conventional therapies. Nanotechnology is an emerging field of science that offers newer possibilities in therapeutics including cancer medicine, specifically by targeted delivery of anticancer drugs. Several phytochemicals are known for their anti-cancer properties and have been regarded as chemopreventive agents. However, the hydrophobic nature of many phytochemicals decreases its bioavailability and distribution, thus showing limited therapeutic effect. Application of nanotechnology to enhance chemoprevention is an effective strategy to increase the bioavailability of phytochemicals and thereby its therapeutic efficacy. The present review focuses on the utility of nanotechnology in RCC treatment and chemopreventive agents of RCC. We have also visualized the future prospects of nanomolecules in the prevention and cure of RCC. [Display omitted]